Latham & Watkins Advises Pi-Cardia in Partnership with Venus Medtech to Bring Leaflex(TM) Aortic Valve Technology to China

Bicoastal team represented Pi-Cardia in the licensing transaction.

July 14, 2020

Venus Medtech (Hangzhou) Inc., the leading transcatheter heart valve medical device player in China, and Pi-Cardia Ltd., a global leader in the development of non-implant catheter-based solutions for treating heart valve calcification, has announced a collaboration to bring Pi-Cardia's Leaflex™ technology to China. Pi-Cardia's Leaflex™ catheter performs mechanical scoring of valve calcification, restoring leaflets' mobility and improving valve hemodynamics.

Latham & Watkins LLP represented Pi-Cardia in the licensing transaction with a corporate team led by New York partner Nathan Ajiashvili and Bay Area partner Judith Hasko, with associate Maya Ziv.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.